8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments

Details for Australian Patent Application No. 2003253418 (hide)

Owner Boehringer Ingelheim Pharma GmbH & Co. KG

Inventors Langkopf, Elke; Mark, Michael; Lotz, Ralf, Richard, Hermann; Eckhardt, Matthias; Maier, Roland; Tadayyon, Mohammad; Himmelsbach, Frank

Agent Davies Collison Cave

Pub. Number AU-B-2003253418

PCT Number PCT/EP03/09127

PCT Pub. Number WO2004/018468

Priority 103 12 353.9 20.03.03 DE; 102 38 243.3 21.08.02 DE

Filing date 18 August 2003

Wipo publication date 11 March 2004

Acceptance publication date 22 April 2010

International Classifications

C07D 473/04 (2006.01) Heterocyclic compounds containing purine ring systems

A61K 9/02 (2006.01) Medicinal preparations characterised by special physical form - Suppositories

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/28 (2006.01) Medicinal preparations characterised by special physical form - Dragees

A61K 9/48 (2006.01) Medicinal preparations characterised by special physical form - Preparations in capsules, e.g. of gelatin, of chocolate

A61K 47/02 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Inorganic compounds

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07D 473/06 (2006.01) Heterocyclic compounds containing purine ring systems

C07D 473/08 (2006.01) Heterocyclic compounds containing purine ring systems

Event Publications

30 October 2003 Complete Application Filed

  Priority application(s): 103 12 353.9 20.03.03 DE; 102 38 243.3 21.08.02 DE

22 April 2004 Application Open to Public Inspection

  Published as AU-B-2003253418

22 April 2010 Application Accepted

  Published as AU-B-2003253418

19 August 2010 Standard Patent Sealed

2 February 2012 Extension of Term of Standard Patents

  Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 01 Nov 2011 For the goods TRAJENTA Linagliptin Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000

28 June 2012 Extension granted

  Boehringer Ingelheim Pharma GmbH & Co. KG The earliest first regulatory approval date provided by the patentee 01 Nov 2011 For the goods TRAJENTA Linagliptin Extension of Term of patent pursuant to Section 77 expires on 01 Nov 2026

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003253419-INTAKE DEVICE

2003253417-CHEMICAL COMPOUNDS